The Role of DLBS1033 in The Management of Acute Non-ST Elevation of Myocardial Infarction (NSTEMI) Without Early Coronary Revascularization
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II/III
Latest Information Update: 22 Apr 2016
Price : $35 *
At a glance
- Drugs Lumbricus rubellus (Primary) ; Aspirin; Clopidogrel
- Indications Myocardial infarction
- Focus Therapeutic Use
- Sponsors Dexa Medica
- 31 Aug 2018 Biomarkers information updated
- 18 Apr 2016 Planned End Date changed from 1 Feb 2018 to 1 Mar 2018.
- 18 Apr 2016 Status changed from recruiting to withdrawn prior to enrolment as the investigational cases were no longer relevant considering the recent implementation of our current national healthcare system.